Haleon (HLN) Liabilities and Shareholders Equity (2021 - 2026)
Haleon's (HLN) quarterly Liabilities and Shareholders Equity came in at $43.7 billion in Q2 2026, little changed on a QoQ basis from $43.7 billion in Q4 2025.
Haleon (HLN) Liabilities and Shareholders Equity (2021 - 2026) Analysis & Trends
Haleon (HLN) has 6 years of Liabilities and Shareholders Equity data on file, last reported at $43.7 billion in Q2 2026.
- Quarterly Liabilities and Shareholders Equity changed N/A year-over-year to $43.7 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $173.6 billion (changed N/A YoY) and the FY2025 annual result came in at $43.4 billion, down 1.05% from the prior year.
- Liabilities and Shareholders Equity was little changed at $43.7 billion in Q2 2026, from $43.7 billion in the prior quarter.
- In the past five years, Liabilities and Shareholders Equity ranged from a high of $56.7 billion in Q2 2022 to a low of $40.8 billion in Q4 2022.
- A 5-year average of $44.5 billion and a median of $43.2 billion in 2023 frame the typical range for Liabilities and Shareholders Equity.
- Annual changes were most pronounced in 2023 — Liabilities and Shareholders Equity fell 24.57% — and 2024, when it climbed 4.2%.
- Tracing HLN's Liabilities and Shareholders Equity over 5 years: stood at $40.8 billion in 2022, then climbed by 3.51% to $42.3 billion in 2023, then gained by 4.2% to $44.0 billion in 2024, then declined by 0.74% to $43.7 billion in 2025, then declined by 0.01% to $43.7 billion in 2026.
- The last three Liabilities and Shareholders Equity figures came in at $43.7 billion (Q2 2026), $43.7 billion (Q4 2025), and $44.0 billion (Q4 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.76 Bn | 42.79 Bn | - | 43.71 Bn |
| 2 | Teva Pharmaceutical Industries | 43.38 Bn | 39.73 Bn | 2.15 Bn | 39.86 Bn |
| 3 | Zoetis | 31.61 Bn | 29.93 Bn | 1.05 Bn | 15.08 Bn |
| 4 | Takeda Pharmaceutical | 28.64 Bn | 22.84 Bn | 5.10 Bn | 98.27 Bn |
| 5 | United Therapeutics | 22.20 Bn | 19.54 Bn | 683.80 Mn | 7.22 Bn |
| 6 | Viatris | 18.82 Bn | 17.93 Bn | 1.46 Bn | 35.04 Bn |
| 7 | Neurocrine Biosciences | 15.67 Bn | 15.28 Bn | 935.80 Mn | 5.36 Bn |
| 8 | Elanco Animal Health | 12.11 Bn | 11.58 Bn | 798.00 Mn | 13.56 Bn |
| 9 | Dr Reddys Laboratories | 10.10 Bn | 9.94 Bn | - | 6.18 Bn |
| 10 | Alkermes | 8.21 Bn | 7.55 Bn | 397.90 Mn | 4.39 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 43.71 Bn |
| Dec 31, 2025 | 43.72 Bn |
| Dec 31, 2024 | 44.04 Bn |
| Jun 30, 2024 | 42.15 Bn |
| Dec 31, 2023 | 42.27 Bn |
| Jun 30, 2023 | 42.75 Bn |
| Dec 31, 2022 | 40.84 Bn |
| Jun 30, 2022 | 56.68 Bn |
| Dec 31, 2021 | 46.44 Bn |